Phio Pharmaceuticals
| Region | Nordamerika |
| ISIN | US71880W2044 |
| Sektor | Biotechnologie |
| Website | http://www.phiopharma.com |
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
| Titel | Autor | Datum |
|---|---|---|
|
In Wahrheit 100 Mal so viel wert?
|
sharedeals | vor ungefähr 6 Jahren |
| Titel | Datum |
|---|---|
| MISC Should Ease Into 2026 Smoothly | vor 3 Tagen |
| MISC Group expands dual-fuel fleet through AET's new Suezmax contracts | vor 4 Tagen |
| MISC Orders LNG Dual-Fuel Suezmax Pair in Fleet Renewal Drive | vor 4 Tagen |
| MISC Posted 60% Jump In Q3 Profit To RM541 Million Despite Lower Revenue | vor 4 Tagen |
| MISC 3Q net profit rises 60%, declares dividend of eight sen per share | vor 4 Tagen |
| Diese Aktien könnten Dich auch interessieren | |
|---|---|
| PayPal (1 Artikel) | |
| Palatin Technologies (4 Artikel) | |
| Premier Gold Mines (1 Artikel) | |
| QIAGEN (1 Artikel) | |
| Alle anzeigen | |